TLR7 TLR7 marker predictive of responsiveness to immunotherapy in a patient with gastrointestinal cancer and use thereof

摘要

The present invention relates to a biomarker for predicting responsiveness to immunotherapy in gastrointestinal cancer patients and uses thereof. More specifically, the present invention relates to, comprising Toll-like receptor 7 (TLR7) genes or proteins encoded by the genes, a marker composition for predicting immunotherapy responsiveness in gastrointestinal cancer patients, a composition for predicting immunotherapy responsiveness, and a method for providing information for predicting immunotherapy responsiveness. The biomarker according to the present invention can be easily obtained as formalin-fixed paraffin embedded tissue, and can be used for classifying immune responses, predicting prognosis, and predicting responsiveness to immunotherapy through analysis of Nanostring gene expression for RNA extracted from cancer patient-derived tissues that can be stored for a relatively long time.